392 related articles for article (PubMed ID: 26598513)
1. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
[TBL] [Abstract][Full Text] [Related]
2. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
de Baat EC; Mulder RL; Armenian S; Feijen EA; Grotenhuis H; Hudson MM; Mavinkurve-Groothuis AM; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD014638. PubMed ID: 36162822
[TBL] [Abstract][Full Text] [Related]
3. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2005 Jan; (1):CD003917. PubMed ID: 15674919
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD003917. PubMed ID: 21678342
[TBL] [Abstract][Full Text] [Related]
5. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2008 Apr; (2):CD003917. PubMed ID: 18425895
[TBL] [Abstract][Full Text] [Related]
7. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients.
Seif AE; Walker DM; Li Y; Huang YS; Kavcic M; Torp K; Bagatell R; Fisher BT; Aplenc R
Pediatr Blood Cancer; 2015 Apr; 62(4):704-9. PubMed ID: 24668949
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
9. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
10. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
[TBL] [Abstract][Full Text] [Related]
11. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.
Swain SM; Vici P
J Cancer Res Clin Oncol; 2004 Jan; 130(1):1-7. PubMed ID: 14564513
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
13. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
[TBL] [Abstract][Full Text] [Related]
14. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
van Dalen EC; van der Pal HJ; Kremer LC
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD005008. PubMed ID: 26938118
[TBL] [Abstract][Full Text] [Related]
15. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
[TBL] [Abstract][Full Text] [Related]
16. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
van Dalen EC; Raphaël MF; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2014 Sep; (9):CD006647. PubMed ID: 25188452
[TBL] [Abstract][Full Text] [Related]
17. Minimizing cardiac toxicity in children with acute myeloid leukemia.
Narayan HK; Getz KD; Leger KJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
[TBL] [Abstract][Full Text] [Related]
18. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Jones RL
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
[TBL] [Abstract][Full Text] [Related]
19. Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.
Kim H; Kang HJ; Park KD; Koh KN; Im HJ; Seo JJ; Lee JW; Chung NG; Cho B; Kim HK; Lee JM; Hah JO; Lee JA; Lee YH; Park SK; Baek HJ; Kook H; Kim JY; Kim HS; Kim HM; Chueh HW; Park M; Yoon HS; Lee MJ; Choi HS; Ahn HS; Kawano Y; Park JW; Hahn S; Shin HY
Cancer Res Treat; 2019 Jan; 51(1):357-367. PubMed ID: 29764117
[TBL] [Abstract][Full Text] [Related]
20. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]